Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
Gregory, Gareth P. , Kumar, Shaji , Mahadevan, Daruka , Walker, Patricia , Wagner‐Johnston, Nina D. , Bannerji, Rajat , Bhutani, Divaya , Chang, Julie , Hernandez‐Ilizaliturri, Francisco J. , Klein, Andreas K. , Pagel, John M. , Rybka, Witold B. , Mohrbacher, Anne, Huang, Mo , Farooqui, Mohammed, Marinello, Patricia, Wagner-Johnston, Nina , Bannerji, Rajat , Bhutani, Divaya , Rybka, Witold , Yee, Andrew J , Huang, Mo , Quach, Hang , Wang, Ding , Escobar, Carolina, Mohrbacher, Ann M., Quach, Hang

Mayo Clinic

Blood Advances | December 31, 2021 | Volume: 6 | Issue: 4 | Pages: 1232-1242

10.1182/bloodadvances.2021005872 | PMID 34972202 Get It

AbstractPreclinical data demonstrated that combining an anti–programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combination may be a potential therapeutic option. The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor activity of the PD-1 inhibitor pembrolizumab plus the CDK9 inhibitor dinaciclib in patients with relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Patients enrolled were ≥18 years of age with a confirmed diagnosis of CLL, DLBCL, or MM. The study included 2 phases: a dose-evaluation phase to determine dose-limiting toxicities and a signal-detection phase. Patients received pembrolizumab 200 mg every 3 weeks plus dinaciclib 7 mg/m2 on day 1 and 10 mg/m2 on day 8 of cycle 1 and 14 mg/m2 on days 1 and 8 of cycles 2 and later. Primary endpoint was safety, and a key secondary endpoint was objective response rate (ORR). Seventy-two patients were enrolled and received ≥1 dose of study treatment (CLL, n = 17; DLBCL, n = 38; MM, n = 17). Pembrolizumab plus dinaciclib was generally well tolerated and produced no unexpected toxicities. The ORRs were 29.4% (5/17, rrCLL), 21.1% (8/38, rrDLBCL), and 0% (0/17, rrMM), respectively. At data cutoff, all 72 patients had discontinued treatment, 38 (52.8%) because of progressive disease. These findings demonstrate activity with combination pembrolizumab plus dinaciclib and suggest that a careful and comprehensive approach to explore anti–PD-1 and CDK9 inhibitor combinations is warranted. This trial was registered at www.clinicaltrials.gov as NCT02684617.
MedTator: a serverless annotation tool for corpus development
Fu, Sunyang , Wang, Liwei , Liu, Sijia , Wen, Andrew , Liu, Hongfang , He, Huan , Fu, Sunyang , Wang, Liwei , Liu, Sijia , Wen, Andrew , Liu, Hongfang , He, Huan

Mayo Clinic

Bioinformatics | December 31, 2021 | Volume: 38 | Issue: 6 | Pages: 1776-1778

10.1093/bioinformatics/btab880 | PMID 34983060 Get It

AbstractSummaryBuilding a high-quality annotation corpus requires expenditure of considerable time and expertise, particularly for biomedical and clinical research applications. Most existing annotation tools provide many advanced features to cover a variety of needs where the installation, integration and difficulty of use present a significant burden for actual annotation tasks. Here, we present MedTator, a serverless annotation tool, aiming to provide an intuitive and interactive user interface that focuses on the core steps related to corpus annotation, such as document annotation, corpus summarization, annotation export and annotation adjudication.Availability and implementationMedTator and its tutorial are freely available from https://ohnlp.github.io/MedTator. MedTator source code is available under the Apache 2.0 license: https://github.com/OHNLP/MedTator.Supplementary informationSupplementary data are available at Bioinformatics online.
Characterization of amyloid‐related imaging abnormality in the DIAN‐TU‐001 trial
Hofmann, Carsten, Wang, Guoqiao , Chen, Charles D., Gauthier, Serge , Holdridge, Karen C. , Klein, Gregory , Mummery, Catherine J. , Preboske, Gregory M., Santacruz, Anna , Yaari, R. , Salloway, Stephen , Clifford, David B., Unit, Dominantly Inherited Alzheimer Network Trials, Joseph‐Mathurin, Nelly , Llibre‐Guerra, Jorge J. , McCullough, Austin , Li, Yan , Wojtowicz, Jakub , Wang, Qing , Gordon, Brian A. , Brooks, William S. , Hsiung, Ging‐Yuek Robin , Jack, Clifford R. , Masellis, Mario , Wallon, David , Xiong, Chengjie , McDade, Eric , Bateman, Randall J. , Benzinger, Tammie L.S. , Unit, Dominantly Inherited Alzheimer Network Trials

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S1 | Pages: No page available

10.1002/alz.056393 Get It

AbstractBackgroundAmyloid‐related imaging abnormalities (ARIA), edema (E) or hemorrhagic (H) type, have been reported in trials of anti‐β‐amyloid passive immunotherapies in sporadic and dominantly inherited Alzheimer Disease (DIAD). However, beyond APOE‐ɛ4 the risk factors and clinical implications of ARIA are not well understood, especially in DIAD populations. Here we characterize ARIA, focusing on ARIA‐E in the DIAN‐TU‐001 trial evaluating gantenerumab and solanezumab in DIAD.MethodThe DIAN‐TU‐001 trial enrolled 194 participants, including 144 DIAD mutation‐carriers receiving gantenerumab (n=52), solanezumab (n=52), or a placebo (n=40). Clinical assessments included the Clinical Dementia Rating (CDR). Imaging assessments included PiB‐PET and safety MR, including T2‐FLAIR and T2*‐GRE. Treatment dosage and APOE‐ɛ4 status were also reported.ResultEleven participants developed a total of 14 ARIA‐E episodes (discovered on scheduled safety MR) and three had associated mild symptoms reported in retrospect (e.g. headache, imbalance disorder). Though one ARIA‐E case was observed in the solanezumab arm, the following results focus on the gantenerumab arm to prevent unblinding. Recipients of gantenerumab were more likely to develop ARIA‐E compared to placebo (odds ratio (OR)=9.29, 95% confidence interval (CI)=[1.1,75.9], p‐value<0.05). ARIA‐E participants were PiB‐PET+ and 60% were CDR>0. APOE‐ɛ4 tends to be associated with risk for developing ARIA‐E (OR=5.0, 95%CI=[1.0,30.4], p‐value=0.055). ARIA‐E were not observed at initial 225mg dose and were first observed after a titration step (within 4‐24 weeks, after 1‐6 injections, Table 1). Time‐to‐resolution of ARIA‐E was 10.4±6.2weeks. Seven of ten ARIA‐E patients paused/reduced dose escalation and three discontinued treatment. Overall, developing ARIA‐E did not increase the odds of trial discontinuation (OR=1.57, 95%CI=[0.34,7.33], p‐value=0.57). ARIA‐E occurred primarily in the occipital lobe (71%) with associated incident ARIA‐H (microhemorrhages or superficial siderosis) in 60% of ARIA‐E participants. ARIA‐E size was associated with microhemorrhage count (Spearman’s rho=0.72, p‐value<0.05), rate of change (rho=0.78, p‐value<0.01), and baseline PiB‐PET (rho=0.68, p‐value<0.05). Normalizing by baseline, PiB‐PET decreased similarly in ARIA‐E+ (‐0.21±0.20) and ARIA‐E‐ (‐0.16±0.20) participants.ConclusionIn DIAD, gantenerumab dose over 225mg increased ARIA‐E risk, possibly more for APOE‐ɛ4 carriers. ARIA‐E was reversible, generally asymptomatic, and without increased odds of trial discontinuation. These aspects of drug response give insights for managing ARIA‐E occurrence in future trials.
Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
Yang, Fang , Wang, Jacqueline , Liu, Baorui , Molina, Julian R. , Wang, Jacqueline F , Wang, Yucai

Mayo Clinic

Cancers | December 28, 2021 | Volume: 14 | Issue: 1 | Pages: 109

10.3390/cancers14010109 | PMID 35008273 Get It

Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) have dramatically changed the landscape of cancer therapy. Both remarkable and durable responses have been observed in patients with melanoma, non-small-cell lung cancer (NSCLC), and other malignancies. However, the PD-1/PD-L1 blockade has demonstrated meaningful clinical responses and benefits in only a subset of patients. In addition, several severe and life-threatening adverse events were observed in these patients. Therefore, the identification of predictive biomarkers is urgently needed to select patients who are more likely to benefit from ICI therapy. PD-L1 expression level is the most commonly used biomarker in clinical practice for PD-1/PD-L1 inhibitors. However, negative PD-L1 expression cannot reliably exclude a response to a PD-1/PD-L1 blockade. Other factors, such as tumor microenvironment and other tumor genomic signatures, appear to impact the response to ICIs. In this review, we examine emerging data for novel biomarkers that may have a predictive value for optimizing the benefit from anti-PD-1/PD-L1 immunotherapy.
Plasma-Soluble Biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) Reflect Acute and Chronic Inflammatory States
Pignolo, Robert J. , McCarrick-Walmsley, Ruth, Qiu, Shirley , Hunter, Jeffrey W. , Barr, Sharon, Zhang, Hui , Wang, Haitao , Qiu, Shirley, He, Kevin , Kaplan, Frederick S.

Mayo Clinic

Journal of Bone and Mineral Research | December 26, 2021 | Volume: 37 | Issue: 3 | Pages: 475-483

10.1002/jbmr.4492 | PMID 34954853 Get It

ABSTRACT Fibrodysplasia ossificans progressiva (FOP) is a progressive, debilitating genetic disease in which skeletal muscle and connective tissue is episodically replaced by heterotopic bone. Discovery of surrogate biomarkers of disease (genotype)-related and flare-up-associated activity of FOP in a readily accessible matrix, such as plasma, would facilitate an understanding of the complex pathophysiology of FOP, aid patient care, and provide a valuable tool for the development and monitoring of potential therapeutics. In a case–control study, using a carefully collected and curated set of plasma samples from 40 FOP patients with the classic ACVR1R206H mutation and 40 age- and sex-matched controls, we report the identification of disease-related and flare-up-associated biomarkers of FOP using a multiplex analysis of 113 plasma-soluble analytes. Adiponectin (implicated in hypoxia, inflammation, and heterotopic ossification) as well as tenascin-C (an endogenous activator of innate immune signaling through the TLR4 pathway and a substrate for kallikrein-7) were highly correlated with FOP genotype, while kallikrein-7 was highly correlated with acute flare-up status. Plasma-soluble biomarkers for FOP support a flare-up-related acute inflammatory phase of disease activity superimposed on a genotypic background of chronic inflammation. © 2021 American Society for Bone and Mineral Research (ASBMR).
Effects of Adipose-Derived Biogenic Nanoparticle-Associated microRNA-451a on Toll-like Receptor 4-Induced Cytokines
Wang, Xinghua , Pham, Anthony , Lu, Kang , Walker, Sierra A. , Davidovich, Irina, Iannotta, Dalila , TerKonda, Sarvam P. , Talmon, Yeshayahu , Wolfram, Joy , Kang, Lu, Talmon, Yeshayahu , Wolfram, Joy , Kang, Lu, Shapiro, Shane A. , Pham, Si M.

Mayo Clinic

Pharmaceutics | December 23, 2021 | Volume: 14 | Issue: 1 | Pages: 16

10.3390/pharmaceutics14010016 | PMID 35056912 Get It

Extracellular vesicles (EVs) are cell-released nanoparticles that transfer biomolecular content between cells. Among EV-associated biomolecules, microRNAs (miRNAs/miRs) represent one of the most important modulators of signaling pathways in recipient cells. Previous studies have shown that EVs from adipose-derived mesenchymal stromal cells (MSCs) and adipose tissue modulate inflammatory pathways in macrophages. In this study, the effects of miRNAs that are abundant in adipose tissue EVs and other biogenic nanoparticles (BiNPs) were assessed in terms of altering Toll-like receptor 4 (TLR4)-induced cytokines. TLR-4 signaling in macrophages is often triggered by pathogen or damage-induced inflammation and is associated with several diseases. This study demonstrates that miR-451a, which is abundant in adipose tissue BiNPs, suppresses pro-inflammatory cytokines and increases anti-inflammatory cytokines associated with the TLR4 pathway. Therefore, miR-451a may be partially responsible for immunomodulatory effects of adipose tissue-derived BiNPs.
Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19
Gillet, A.S. , Zu, Yuanhao, Brown, Margo, Pham, Thaidan , Yoshida, Yilin , Douglas, Ivor S. , Moore, Mathew, Tea, Kevin, Wetherbie, Andrew, Stevens, Rachael, Lefante, John J., Shaffer, Jeffrey G. , Armaignac, Donna Lee , Belden, Katherine A. , Kaufman, Margit, Heavner, Smith F. , Danesh, Valerie , Hill, Catherine A. St., Boman, Karen , Bansal, Vikas , Kumar, Vishakha K. , Group, Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator, Mesland, Jean-Baptiste , Henin, Pierre , Petre, Hélène, Buelens, Isabelle, Gérard, A , Granado, Rolando Claure-Del, Vega-Terraza, Esdenka, Iturricha-Cáceres, Maria F., Garza, Rubén , Chan, Victoria , Gavidia, Oscar Y., Pachon, Felipe, Tawheed, Ahmed , Pineda, Estela , Guillen, Gabina María Reyes, Soto, Helin Archaga, Lizardo, Ana Karen Vallecillo, Segu, Smitha, Chakraborty, T., Joyce, Epcebha, Kasumalla, Phani Sreeharsha, Vadgaonkar, Girish, Ediga, Rekha, Basety, Shilpa, Dammareddy, Shwetha, Raju, Umamaheswara, Manduva, Janaki, Kolakani, Naresh, Sripathi, Shreeja , Chaitanya, Sheetal, Parameswaran, Sreejith , Parthiban, Magesh, Menu, P., Daga, Mardul Kumar, Agarwal, Munisha , Rohtagi, Ishan, Papani, Sridhar, Kamuram, Mahesh, Agrawal, Kamlesh Kumar , Baghel, Vijendra, Patel, K, Mohan, Surapaneni Krishna, Jyothisree, Ekambaram, Dalili, Nooshin , Nafa, Mohsen, Matsuda, Wataru , Suzuki, Reina , Horikita, Sho, Kodate, Akira, Takahashi, Yuki , Moriki, Koyo, Iwasaki, Yudai , Rodríguez‐Gutiérrez, René , Gonzale, Jose Gerardo, Salcido‐Montenegro, Alejandro , Hassan-Hanga, Fatimah , Gezawa, Abubakar Shehu, Kabir, Halima , Amole, Taiwo Gboluwaga , Haliru, Dalha Gwarzo, Ibrahim, Abdullahi S., Asghar, Muhammad Sohaib , Syed, Mashaal , Naqvi, Syed Anosh Ali, Заболотских, И. Б. , Alamoudi, Razan K., Alsharif, Hassan, Almazwaghi, Sarah A., Elsakran, Mohammed S., Aid, M., Darwich, Mouaz A., Hagag, Omnia M., Ali, Salah A., Rocacorba, Alona, Supeña, Kathrine, Juane, Efren Ray, Medina, Jenalyn, Baduria, Jowany, Amer, Marwa , Dahhan, Talal, Kseibi, Eiad, Butt, Abid Shahzad, Khurshid, Syed Moazzum, Rabee, Muath, Abujazar, Mohammed, Alghunaim, Razan K, Abualkhair, Maal, AlFirm, Abeer Turki, Alarifi, Mohammed I, Macarambon, Jara Mia, Bukhari, Ahmad Abdullah, Albahrani, Hussian A, Aldossary, Kaltham M., Zoran, Marija Zdravkovic, Popadic, Viseslaz, Bojicic, Jovana, Predrag, Stevanović, Stojakov, Dejan , Ignjatovic, Duska K., Bojicic, Suzana C, Bobos, Mariana M, Nenadić, Irina , Zaric, Milica S., Djuric, Marko , Djukic, Vladimir R., Teruel, Santiago, Martin, Belen C., Bilgin, Huseyin, Dodd, Kenneth W. , Goodmanson, Nicholas, Hesse, Kathleen, Bird, P. H., Weinert, Chauncey, Schoenrade, Nathan, Altaher, Abdulrahman, Mayar, Esmael, Aronson, Matthew, Cooper, Tyler, Logan, Monica, Miner, Brianna, Papo, Gisele, Siegal, Eric M., Runningen, Phyllis, Patel, Love , Melamed, Roman , Tierney, David M. , Raj, Vino S., Mazumder, Narayana, Hill, Catherine St., Kirkland, Lisa L., Schmitz, Nova J., Sigman, Alena, Hall, Joan, Raval, Abhijit, Franks, Andrea S. , Jarvis, Jennifer M., Kharbanda, Anmol, Jhajhria, Sunil, Fyffe, Zachary, Capizzi, Stephen A., Alicie, Bethany, Green, Martha, Corckarell, Lori, Drennan, A. M., Dubuque, Kathleen, Fambrough, Tonya, Gasaway, Nikole, Krantz, Briana, Nebi, Peiman, Orga, Jan, Serfass, Margaret, Simion, Alina, Warren, Kimberly R., Wheeler, Cassie, Woolman, C. J., Christie, Amy B. , Adiga, Rajani, Moyer, A, Verghese, George M., Forehand, Chirsty C, Sabov, Moldovan, Zaidi, Fatema, Tissavirasingham, Fiona, Malipeddi, Dhatri , Campbell, Beth Salvagio , Wilson, Cathleen, Rivers, Patrick , Brinks, Jonathan, Mongoh, Mokenge Ndiva, Gilson, Boris, Armaignac, Donaa Lee, Parris, Don, Zuniga, Maria Pilar, Vargas, Ilea, Boronat, Viviana, Hutton, Anneka, Kaur, Navneet , Neupane, Prashank, Sadule-Rios, Nohemi, Rojas, Lourdes M. , Neupane, Aashish, Rivera, Priscilla, Carlos, Carlos Valle, Amin, Mahesh, Schelle, Mary E, Steadham, Amanda, McBride, Cameron , Abraham, Jocelyn, Richards, Katherine , Collins, Keegan, Antony, Preethi, Dubrocq, Gueorgui , Davis, Amber, Hammers, Marissa J, McGahey, Ill M, Farris, Amanda C., Priest, Elisa L. , Korsmo, Robyn, Fares, Lorie, Skiles, Kathy, Shor, Susan M, Burns, Kenya, Flores, Melody, Newman, Lindsay, Wilk, Debora A., Ettlinger, Jason, Bomar, Jaccallene, Darji, Himani, Arroliga, Alejandro C. , Dowell, Corrie A., Gonzales, Gabriela “ Hope”, Garcia, Michael A. , Colona, Mia R., Kibbelaar, Zoé A. , Leong, Michael S. , Wallman, Daniel , Soni, Kanupriya , Maccarone, Jennifer , Gilman, Joshua, Devis, Ycar, Chung, Joseph, Paracha, Munizay , Lumelsky, David , DiLorenzo, Madeline A. , Abdurrahman, Najla, Johnson, Shelsey W. , Hersh, Maj Andrew M., Wachs, Stephanie, Swigger, Brittany S., Sattler, L, Moulton, Michael N., Zammit, Kimberly, Loeffler, William, Tirupathi, Raghavendra , Tang, Alymer, Safi, Arshad M., Green, Cindy, Newell, J.D., Ramani, Naga, Ganti, Bhavani Harika, Ihle, R , Davis, Elaine , Martin, Shelda A, Sayed, Imran A., Strom, Larisa, Lee, Giyoung , Burnett, Ryan H., Sydney, Guy I. , Traynor, Danielle M., White, Joshua, Khan, Aftab, Dhahwal, Rahul, Ahmed, Farzin, Deonarine, Chrispoter, Jones, Ashley, Shaikh, Mohammad Ali, Preston, David A. , Chin, Jeanette, Duggal, Abhijit, Rajendram, Prabalini , Mehkri, Omar , Biehl, Michelle, Houltham, Stuart, Kind, Alexander, Ashok, Kiran, Poynter, Bryan, Beukemann, Mary, Rice, Richard, Gole, Susan, Shaner, Valerie , Conjeevaram, Adarsh, Ferrari, Michlelle, Alappan, Narendrakumar, Minear, Steven , Hernández-Montfort, Jaime , Nasim, Syed Sohaib, Sunderkrishnan, Ravi, Sahoo, Debasis , Milligan, Patrick S., Koglin, Joy M., Gibson, Regina, Johnson, Lana, Preston, Felicia, Scott, Crimson, Nungester, Bethany, Byrne, Dana , Grant, Katie, Doktar, Katherine L, Porto, Maura C, Kaplan, Olgo, Schonewald, Brian, Woodford, Ashley L., Tsai, Alan , Reid, Savina, Bhowmick, Kuntal, Daneshpooy, Saba , Mowdawalla, Cyrus , Dave, Trishna Akshay, Crudeli, Wilhemina Kennedy Connor, Ferry, Chirstopher, Nguyen, Long , Modi, Sneha, Padala, Niharika, Patel, Pavan Jitendra, Lin, Belle, Qiuyun, Jamie, Liu, Fan Mandi, Kota, Rasagna, Banerjee, Annesha , Daugherty, Steven K., Atkinson, Sam, Shrimpton, Kelly, Ontai, Sidney , Contreras, Brian, Obinwanko, Uzoma, Amamasi, Nneka, Sharafi, Amir, Lee, Sarah , Esber, Zahia , Jinjvadia, Chetna, Krishnamoorthy, Vijay , Kraft, Bryan , Pulsipher, Aaron, Friedman, Eugene, Mehta, Sachin , Kaufman, Margit, Lobel, G, Gandhi, Nisha, AbdelAty, Amr M. , Shaji, Elizabeth, Lim, Kiana, Marte, Juan M., Sosa, Dani Ashley, Benjenk, Ivy , Prasanna, Nivedita, Perkins, Nicholas , Roth, Prera J, Litwin, Alain H. , Pariyadath, Ananda, Moschella, Phillip , Llano, Trayson, Waller, Christine, Kallies, Kara J. , Thorsen, Jonean , Fitzsimmons, Alec , Olsen, H. L., Smalls, Normal, Davis, S., Jovic, Valentina, Masuda, M, Hayes, Amanda, Nault, Katharine, Snow, William G., Liptak, Riley, Durant, Hannah, Pendleton, Valerie, Nanavati, Alay, Mrozowsk, Risa, Doubleday, Erica, Liu, Yuk Min, Zavala, Sarah , Shim, Esther, Reilkoff, Ronald A., Eichen, Sarah, Goertzen, Lexie, Rajala, Scott, Feussom, Ghislaine, Junia, Christine, Lichtenberg, Robert, Sidhu, Hasrat, Espinoza, Diana , Rodrigues, Shelden , Zabala, Marai Jose, Susheela, Ammu , Hatharaliyadda, Buddhi, Rameshkumar, Naveen, Kasireddy, Amulya, Beltran, Lisseth, Chaugule, Akshata, Patil, Namrata, Patil, Ruhi, Cartin‐Ceba, Rodrigo , Sen, Ayan , Talaei, Fahimeh , Domecq, Juan Pablo , Gajic, Ognjen, Sharma, Mayank , Qamar, Shahraz , Morales, Diana J. Valencia , Nou, Abigail T. La, Bogojevic, Marija , Sanghavi, Devang , Franco, Pablo Morno, Ganaphadithan, Karthik, Saunders, Hollie , Fleissner, Zachary, Mateus, Alejandra Yu Lee, Kaur, Nirmaljot , Giri, Abhisekh, Hasan, Mohammed Mustafa, Donepudi, Ashrita , Khan, Syed Anjum , Jain, Nitesh , Koritala, Thoyaja , Nanchal, Rahul , Peterson, Jennifer , Yamanaka, Travis, Barreras, Nicholas A., Markos, Michael, Fareeduddin, Anita, Mehta, Rohan, Venkata, Chakradhar , Engemann, Miriam, Mantese, Annamarie, Tarabichi, Yasir , Wang, Christine, Kotekal, Dhatri, Bierwirth, Adriana C. Briceno, Orellana, Gabriela, Catalasan, Gerardo , Ahmed, Shohana, Salinas, Ivania, Nogal, Genesis Del, Tejada, Ángel Morales-Martínez de, Chen, Jen‐Ting , Hope, Aluko A. , Tsagaris, Zoe, Ruen, Elise, Hambardzumyan, Aram, Siddiqi, Nasar A, Jurado, Lesly, Tincher, Lindsey, Brown, Carolyn , Aulakh, Bhagat , Bandy, Jennifer A., Kreps, Lisa M., Bollinger, Dwan R, Stienecker, Roger Scott , Melendez, Andre G, Brunner, Tressa A., Budzon, Sue M., Heffernan, J., Souder, Janelle M., Miller, Tracy L., Maisonneuve, A., Redfern, Roberta E. , Shoemaker, Jessica, Micham, Jennifer, Kenney, Lynn, Naimy, Gabriela, Pulver, Kerry P J, Yehle, Jennifer, Weeks, Alicia, Inman, T., Delmonaco, Brain L, Franklin, Anthony , Heath, Mitchell, Vilella, Antonia L. , Kutner, Sara B., Clark, Kacie , Anderson, Harry L, Rajkumar, Dixy, Abunayla, Ali, Heiter, Jerrilyn, Zaren, Howard A. , Smith, Stephanie J., Lewis, Grant C., Seames, Lauren, Farlow, Cheryl, Miller, Judy, Broadstreet, Gloria, Martinez, Anthony , Allison, Micheal, Mittal, Aniket, Ruíz, Rafael Azuar , Skaanland, Aleta, Patel, Umang, Hodge, Jordesha, Patel, Krunal Kumar, Dalal, Shivani , Kavani, Himanshu , Joseph, Sam W. , Bernstein, Michael, Goff, Ian K., Naftilan, Matthew, Mathew, Amal , Williams, Debora, Murdock, Sue, Ducey, Maryanne, Nelson, Kerianne, Mitchel, James, Cox, Sylvan, Amzuta, Ioana, Shah, Amish , Modi, Ritu, Al-Khalisy, Hassan, Masuta, Pradeep, Schafer, Melissa , Wratney, Angela, Carter, K., Olmos, M. A. Martinez, Parker, Brittany M, Quintanilla, Julio, Craig, Tara A, Clough, B., Jameson, J, Jones, Tacy L, Ayers, Shonda C., Harrell, Amy B., Brown, Brent R., Darby, Caleb, Page, Kristy, Brown, Amanda, McAbee, Jessie, Baram, Michael , Weber, Devin , DePaola, Rosalie, Xia, Yuwei , Carter, Hudson, Tolley, A. E., Ferranti, Mary, Steele, Mark P., Kemble, Laurie, Sethi, Joshua, Han, Chung Cheng, Pagliaro, Jaclyn , Husian, Abdurrahman, Zawaydeh, Qais , Sines, B. , Markotić, Dragana, Bošnjak, Ivana, Nicholson, Susannah E. , Jonas, Rachelle B., Dement, AnnaRose E, Tang, William , DeRose, Mark, Villarreal, Robert E, Dy, Rajany , Lardino, Alfredo, Sharma, Jill H., Czieki, Richard, Christopher, Julia, Lacey, Ryan, Mashina, Marwan , Patel, Kushal, Gomaa, Dina , Goodman, Micahel, Spuzzillo, Anthony , Shinn, John O., Baslanti, Tezcan Ozrazgat, Omalay, George, Hashemighouchani, Haleh , Cupka, Julie S , Galet, Colette , Hubbard, Janice, Nazir, Usman, Rampon, Garrett , Riggle, Jake, Dismag, Nathan, Lenhardt, Rainer, Cavallazzi, Rodrigo , Jerde, Ann, Black, Alexa, Polidori, A., Griffey, Haily, Winkler, J., Brenzel, Thomas, Alvarez, Rodger A, Alarocon-Calderon, Amarilys, Sosa, Marie Anne , Mahabir, Sunita, Patel, Mausam , Parker, Pauline, Admon, Andre, Hanna, Sinan, Pliakas, Maria , Wolski, Ann, Cirino, Jennifer, Geiger, Grant , Njai, Abdoulie , Saad, Baraa M., Chuan, Byron, Rawal, Sagar L, Piracha, Manal, Levin, Nicholas M. , Suslavich, Kayte , Tsolinas, Rachel , Fica, Zachary , Skidmore, Chloe R., Stapleton, Renee D., Dixon, Anne E. , Johnson, Olivia, Ardren, Sara S., Burns, Stephanie, Raymond, Anna, Gonyaw, Erika, Hodgdon, Kevin , Houseger, Chole, Lin, Benjamin R. , McQuesten, Karen, Grimm, Heidi Pecott-, Sweet, Julie, Ventrone, Sebastian, Khandelwal, Nita , Lovelace-Macon, Lara, Garimella, Navya, Dow, Denisse Bazan, Rahman, Rania Abdul, Mulrow, Mary, Wilfong, Erin M. , Vela, Kelsi, Harris, Lynne, Cusson, Bruce, Fowler, Jacob , VanEenenaam, David P., Mckinney, Glen , Udoh, Imoh, Johnson, Kathleen N. , Michelson, Andrew P. , Haulf, Sara S, Lynch, Lauren, Steinbery, Aaron, Braus, Nicholas, Pattan, Vishwanath , Papke, J, Jimada, Ismail, Mhid, Nida, Chakola, Samuel, Sheth, Kevin N., Ammar, Abdalla , Lopez, Victor Torres , Khosla, Akhil , Gautam, Samir C. , Lee‐Mateus, Alejandra Yu , Bansal, Vikas , Yu Lee-Mateus, Alejandra , Kaur, Nirmaljot , Asghar, Muhammad S , Redfern, Roberta E , Denson, Joshua L. , Mauvais‐Jarvis, Franck , Cheruku, Sreekanth , Deo, Neha , Walkey, Allan J. , Kashyap, Rahul , Group, Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator, Clevenbergh, Philippe Albert , Granado, Rolando Claure‐Del , Mercado, Jose A, Garza, Ruben, Chu, Eric, Chan, Victoria, El‐Kassas, Mohamed , Chakraborty, Tuhin, Cherian, Anusha , Menu, Priya A, Sanui, Masamitsu , Itagaki, Yuki , Shiga, Takuya , Camacho-Ortíz, Adrián , Galadanci, Hadiza , Syed, Mashaal, Musaeva, Tatiana Sergeevna , Bawazeer, Mohammed Abdullah , Alghunaim, Razan K, Almazyad, Mohammed , Asfina, Kazi Nur , Klašnja, Slobodan , Kovačević, Bojan , Teruel, Santiago Y, Sili, Uluhan , Ay, Pınar , Bird, Paige, Schoenrade, Nathan, Hall, Joan, Franks, Andrea, Drennan, Amelia, Warren, Kimberly, Ashley, Dennis W. , Sikora, Andrea , Bruning, Rebecca, Jones, Timothy W, Mosier, Jarrod , Lutrick, Karen , Vincent, Gregory, Howard, Christopher M. , Garner, Orlando , Mathew, Sindhu, Dubrocq, Gueorgui , Waikar, Sushrut S. , Leong, Michael, McGrath, Patrick J, Chilbert, Maya R. , Green, Cindy, Ihle, Rayan E, Martin, Shelda A., Gist, Katja M. , Chiotos, Kathleen , Blatz, Allison M. , Surani, Salim , White, Joshua, Khan, Aftab, Preston, David, Vachharajani, Vidula , Dugar, Siddharth , Sacha, Gretchen , Kind, Alexander, Gole, Susan, Gupta, Sandeep , Schorr, Christa , Siegler, James E. , Bartz, Raquel R. , Mehta, Sachin, Kaufman, Margit, Abdelaty, Amr, Yamane, David , Pariyadath, Anand, Olsen, Haley, Smith, Michael A. , Snow, William, Heneghan, Julia A. , Tang, Ben, Goyes, Daniela , Maldonado, Génessis , Khan, Hassan, Gajic, Ognjen , Tekin, Aysun , Lal, Amos , O’Horo, John C. , Singh, Romil , Nou, Abigail La, Zec, Simon , Guru, Pramod , Garcia, Juan, Yarrarapu, Siva Naga S. , Bergl, Paul A. , Peterson, Jennifer L, Perzynski, Adam T. , Wang, Christine, Matute, Carlos , Hamdan, Ahmad, Tejada, Angel, Tripathi, Sandeep , Inman, Terra, Moore, Danielle, Anderson, Harry L, Miller, Judy, Ruiz, Rafael, Ross, Robert, Joseph, Sam, Block, Jason, O’Brien, Connor , Carter, Kristina L, Olmos, Michael, Gupta, Neha , Darby, Caleb, Tolley, Aaron, Malhotra, Atul , Bice, Thomas J. , Bosnjak, Ivana, Vail, Emily A. , Tang, William, Villarreal, Roberto E., Patel, Kushal, Wakefield, Devin, Bihorac, Azra , Ruppert, Matthew M. , McGonagill, Patrick W. , Wang, David , Allan, Lauren , Badheka, Aditya V. , Chegondi, Madhuradhar , Akça, Ozan , Polidori, Allison, Winkler, Justin, Chanderraj, Rishi , Dandachi, Dima , Regunath, Hariharan , Camazine, Maraya , Saad, Baraa, Shah, Faraaz A , Tonna, Joseph E. , Lin, Benjamin, Pecott-Grimm, Heidi, West, T. Eoin , Caldwell, Ellen , Akhter, Murtaza , Khanna, Ashish , Lyons, Patrick G. , Lynch, Lauren M, Nguyen, Nguyet Minh , Papke, Jessica, Ammar, Mahmoud A , Dela Cruz, Charles S

Mayo Clinic

JAMA Network Open | December 22, 2021 | Volume: 4 | Issue: 12 | Pages: e2140568

10.1001/jamanetworkopen.2021.40568 | PMID 34935924 Get It

Inhibition of mTOR or MAPK ameliorates vmhcl/myh7 cardiomyopathy in zebrafish
Li, Jiarong , Zhu, Ping , Shih, Yu-Huan, Wang, Mingmin , Zhang, Yuji , Xu, Xiaolei , Bu, Haisong, Ding, Yonghe , Lin, Xueying , Wang, Mingmin , Bu, Haisong

Mayo Clinic

JCI Insight | December 21, 2021 | Volume: 6 | Issue: 24 | Pages: No page available

10.1172/jci.insight.154215 | PMID 34935644 Get It

Myosin heavy chain 7 (MYH7) is a major causative gene for hypertrophic cardiomyopathy, but the affected signaling pathways and therapeutics remain elusive. In this research, we identified ventricle myosin heavy chain like ( vmhcl ) as a zebrafish homolog of human MYH7 , and we generated vmhcl frameshift mutants. We noted vmhcl -based embryonic cardiac dysfunction (VEC) in the vmhcl homozygous mutants and vmhcl -based adult cardiomyopathy (VAC) phenotypes in the vmhcl heterozygous mutants. Using the VEC model, we assessed 7 known cardiomyopathy signaling pathways pharmacologically and 11 candidate genes genetically via CRISPR/Cas9 genome editing technology based on microhomology-mediated end joining (MMEJ). Both studies converged on therapeutic benefits of mTOR or mitogen-activated protein kinase (MAPK) inhibition of VEC. While mTOR inhibition rescued the enlarged nuclear size of cardiomyocytes, MAPK inhibition restored the prolonged cell shape in the VEC model. The therapeutic effects of mTOR and MAPK inhibition were later validated in the VAC model. Together, vmhcl/myh7 loss of function is sufficient to induce cardiomyopathy in zebrafish. The VEC and VAC models in zebrafish are amenable to both efficient genetic and chemical genetic tools, offering a rapid in vivo platform for discovering candidate signaling pathways of MYH7 cardiomyopathy.
Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Reichert, Zachery R. , Kasputis, Tadas, Abusamra, Sophia M. , Kasputis, Amy , Haruray, Saloni , Wang, Yugang , Williams, Shamara , Singhal, Udit , Alva, Ajjai , Cackowski, Frank C. , Caram, Megan E.V. , Palmbos, Phillip L. , Yentz, Sarah , Smith, David C. , Alumkal, Joshi J. , Morgan, Todd M. , Abusamra, Sophia M , Haruray, Saloni , Williams, Shamara , Singhal, Udit , Cackowski, Frank C , Alumkal, Joshi J , Morgan, Todd M , Reichert, Zachery R , Nallandhighal, Srinivas , Palmbos, Phillip

Mayo Clinic

International Journal of Molecular Sciences | December 21, 2021 | Volume: 23 | Issue: 1 | Pages: 4

10.3390/ijms23010004 | PMID 35008431 Get It

The substantial biological heterogeneity of metastatic prostate cancer has hindered the development of personalized therapeutic approaches. Therefore, it is difficult to predict the course of metastatic hormone-sensitive prostate cancer (mHSPC), with some men remaining on first-line androgen deprivation therapy (ADT) for several years while others progress more rapidly. Improving our ability to risk-stratify patients would allow for the optimization of systemic therapies and support the development of stratified prospective clinical trials focused on patients likely to have the greatest potential benefit. Here, we applied a liquid biopsy approach to identify clinically relevant, blood-based prognostic biomarkers in patients with mHSPC. Gene expression indicating the presence of CTCs was greater in CHAARTED high-volume (HV) patients (52% CTChigh) than in low-volume (LV) patients (23% CTChigh; * p = 0.03). HV disease (p = 0.005, q = 0.033) and CTC presence at baseline prior to treatment initiation (p = 0.008, q = 0.033) were found to be independently associated with the risk of nonresponse at 7 months. The pooled gene expression from CTCs of pre-ADT samples found AR, DSG2, KLK3, MDK, and PCA3 as genes predictive of nonresponse. These observations support the utility of liquid biomarker approaches to identify patients with poor initial response. This approach could facilitate more precise treatment intensification in the highest risk patients.